Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of ACT-1014-6470 in healthy volunteers
NL-OMON48421Phase 1Completed
- Sponsor
- Idorsia
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACT-1014-6470 in Inflammatory Disorders (4 arms), sponsored by Idorsia. Primary endpoint: AUC0-inf. Started Nov 2019; status: completed.
02
Drugs
ACT-1014-6470
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NL-OMON48421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48421.